CRT Improved Clinical Response UK Trial

Cardiac Failure Clinical Trial

— CRICKET  

Official title:

CRT Improved Clinical Response UK Trial: A Multi-centre, Prospective, Randomized, Cross-over, Double Blind Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02669134
• Other study ID #: 147-2015-PL
• Status: Withdrawn
• Phase: Phase 3
• Start date: March 2016
• Est. completion date: September 2018

Study information

• Verified date: August 2023
• Source: Aston University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of the CRICKET study is demonstrate that AV and VV optimization using SonR improves LV reverse remodeling response to CRT, compared with 'Fixed Settings' (FS) after 6 months of treatment. In this investigator-initiated, multi-centre, 2:2 factorial design, randomized, two-arm, double-blinded, cross-over, prospective trial, CRT recipients will be randomized to 'SonR' atrioventricular (AV) and ventricular-ventricular (VV) optimization or 'fixed settings'. The primary endpoint is an absolute reduction in left ventricular end-systolic volume.

Description:

This is an investigator-initiated, multi-centre, 2:2 factorial design, randomized, two-arm, double-blinded, cross-over, prospective trial

Main study objectives

The main objective of the CRICKET study is demonstrate that AV and VV optimization using SonR improves LV reverse remodeling response to CRT, compared with 'Fixed Settings' (FS) after 6 months of treatment.

Study endpoints

Primary endpoint: The primary endpoint is a reduction (absolute difference) in LVESV with SonR vs FS after 6 months of treatment. The difference intra-patient of absolute change of LVESV value will be compared between two treatments: "SonR optimization" vs. "FS", defined as a sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous).

Secondary endpoints:

Change in 6 MWT distance Change in NYHA class Change in quality of life Change in patient global assessment (EQ-5D) Change in Quality of life (MLWHF questionnaire) Change in LVEF AF burden Adverse Events

Number of subjects

Two hundred (200) patients will be enrolled. All patients will be implanted with the SonRtip bipolar atrial lead and a LivaNova (Sorin) CRT-D device offering both SonR optimization algorithm and atrio-biventricular pacing. Patients will be assigned to either the treatment or control arms, employing a 1:1 randomization with up to 100 patients in each of the 2 groups: Study Group (SonR CRT Optimization programmed "AV+VV") and Control Group ("Fixed Settings" (FS), defined as a sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous); SonR CRT Optimization programmed "Off"). After the first 6 months, patients will be crossed-over to the alternative arm for another 6 months. There will be no washout period.

Duration of the clinical investigation

The study inclusion phase is expected to last approximately 1.5 years.

Follow-ups

Patients will be evaluated at baseline and randomized prior to implantation to SonR optimization or FS. A further clinical assessment, ECG and echocardiography will be undertaken at 6 months. At this point, patients will be crossed over to the other arm for another 6 months. The study closes following a further clinical and echocardiographic assessment at 12 months.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eligible for implantation of a CRT-D device according to current NICE or ESC guidelines;

• In sinus rhythm;

• NYHA class II, III or IV

• Have reviewed, signed and dated an informed consent

Exclusion Criteria:

• Inability to do a 6 min walk test.

• Previous implant with a pacemaker, an ICD or a CRT device (except upgrade from single chamber ICD with a fully functional defibrillation lead) not under recall or surveillance);

• Persistent atrial arrhythmias (or cardioversion for atrial fibrillation) within the past month;

• Ventricular tachyarrhythmia of transient or reversible causes such as acute myocardial infarction (MI), digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment;

• Incessant ventricular tachyarrhythmia;

• Unstable angina, or acute MI, Coronary Artery Bypass-Grafting (CABG), or Percutaneous Coronary Intervention (PCI) within the past 4 weeks;

• Correctable valvular disease that is the primary cause of heart failure;

• Indication for valve repair or replacement;

• Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the previous 3 months);

• On transplant waiting list;

• Previous heart transplant;

• Already included in another clinical study that could confound the results of this study;

• Life expectancy less than 1 year;

• Inability to understand the purpose of the study;

• Unavailability for scheduled follow-up or refusal to cooperate;

• Age of less than 18 years;

• Pregnancy;

• Drug addiction or abuse;

• Under guardianship.

Related Conditions & MeSH terms

• Cardiac Failure
• Heart Failure

Intervention

Other:
• Device programming
SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed "AV+VV"

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Aston University	University Hospital Birmingham NHS Foundation Trust

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Left ventricular end-systolic volume (LVSV)	Reduction in LVESV with SonR vs FS after 6 months of treatment	6 months
Secondary	Walking distance on 6 -minute walk test	Change in 6 MWT distance	6 months
Secondary	NYHA class	Change in NYHA class	6 months
Secondary	Quality of life - general (non-disease specific)	Change in quality of life, assessed using EQ-5D (section 1)	6 months
Secondary	Patient global assessment	Change in patient global assessment (included in EQ-5D, section 2)	6 months
Secondary	Disease-specific quality of life (heart failure)	Change in quality of life (MLWHF questionnaire)	6 months
Secondary	Left ventricular ejection fraction	Change in LVEF	6 months
Secondary	AF burden	AF burden according to mode-switches	6 months
Secondary	System safety assessed by Adverse Events	Report all Adverse Events	6 months